{"id":123811,"date":"2026-06-19T13:17:57","date_gmt":"2026-06-19T07:47:57","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=123811"},"modified":"2026-06-19T13:17:59","modified_gmt":"2026-06-19T07:47:59","slug":"corona-remedies-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/","title":{"rendered":"CORONA Remedies Share Price Target 2026 Analyst Forecast Bull and Bear Case"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>The CORONA Remedies share price target 2026 is Rs 2,200, implying approximately 20 percent upside from the current market price of Rs 1,833 (NSE: CORONA). With Q4 FY26 results released in 2026 and Pharmaceutical Formulations and APIs tailwinds in focus, the Rs 2,200 price objective is supported by the FY27 earnings recovery thesis.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/corona\/corona-remedies-ltd-share-price-today\">CORONA Remedies<\/a> (NSE: CORONA) is a Pharmaceutical Formulations and APIs company trading at Rs 1,833 with a market capitalisation of Rs 1,833 crore. Analysts have set the <strong>CORONA Remedies share price target<\/strong> at Rs 2,200 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#CORONA_Remedies_Share_Price_Target_2026_Key_Takeaways\" title=\"CORONA Remedies Share Price Target 2026: Key Takeaways\">CORONA Remedies Share Price Target 2026: Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#CORONA_Remedies_Company_Overview\" title=\"CORONA Remedies Company Overview\">CORONA Remedies Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Why_Is_the_CORONA_Remedies_Share_Price_Target_Set_at_Rs_2200_for_2026\" title=\"Why Is the CORONA Remedies Share Price Target Set at Rs 2,200 for 2026\">Why Is the CORONA Remedies Share Price Target Set at Rs 2,200 for 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#FY27_Earnings_Recovery_and_Revenue_Acceleration\" title=\"FY27 Earnings Recovery and Revenue Acceleration\">FY27 Earnings Recovery and Revenue Acceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Structural_Sector_Tailwinds_in_Pharmaceutical_Formulations_and_APIs\" title=\"Structural Sector Tailwinds in Pharmaceutical Formulations and APIs\">Structural Sector Tailwinds in Pharmaceutical Formulations and APIs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\" title=\"RBI Rate Cut Cycle and Lower Cost of Capital\">RBI Rate Cut Cycle and Lower Cost of Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Union_Budget_2026-27_Capex_Push_and_Policy_Support\" title=\"Union Budget 2026-27 Capex Push and Policy Support\">Union Budget 2026-27 Capex Push and Policy Support<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#FII_Flow_Normalisation_After_the_2026_Tariff_Shock\" title=\"FII Flow Normalisation After the 2026 Tariff Shock\">FII Flow Normalisation After the 2026 Tariff Shock<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#CORONA_Remedies_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\" title=\"CORONA Remedies Share Price Targets: Short Term, 12 Month, and Long Term\">CORONA Remedies Share Price Targets: Short Term, 12 Month, and Long Term<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Short_Term_CORONA_Remedies_Share_Price_Target\" title=\"Short Term CORONA Remedies Share Price Target\">Short Term CORONA Remedies Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#12-Month_CORONA_Remedies_Share_Price_Target_2026\" title=\"12-Month CORONA Remedies Share Price Target 2026\">12-Month CORONA Remedies Share Price Target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Long_Term_CORONA_Remedies_Share_Price_Target_FY27_to_FY28\" title=\"Long Term CORONA Remedies Share Price Target: FY27 to FY28\">Long Term CORONA Remedies Share Price Target: FY27 to FY28<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Bull_Case_and_Bear_Case_Scenarios_for_CORONA_Remedies_in_2026\" title=\"Bull Case and Bear Case Scenarios for CORONA Remedies in 2026\">Bull Case and Bear Case Scenarios for CORONA Remedies in 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Bull_Case_CORONA_Remedies_Share_Price_Target_Rs_2650\" title=\"Bull Case CORONA Remedies Share Price Target: Rs 2,650\">Bull Case CORONA Remedies Share Price Target: Rs 2,650<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Bear_Case_CORONA_Remedies_Share_Price_Target_Rs_1450\" title=\"Bear Case CORONA Remedies Share Price Target: Rs 1,450\">Bear Case CORONA Remedies Share Price Target: Rs 1,450<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Key_Risks_That_Could_Derail_the_CORONA_Remedies_2026_Price_Objective\" title=\"Key Risks That Could Derail the CORONA Remedies 2026 Price Objective\">Key Risks That Could Derail the CORONA Remedies 2026 Price Objective<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Global_Macro_and_US_Tariff_Headwinds\" title=\"Global Macro and US Tariff Headwinds\">Global Macro and US Tariff Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#FY27_Earnings_Miss_and_Guidance_Risk\" title=\"FY27 Earnings Miss and Guidance Risk\">FY27 Earnings Miss and Guidance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Competitive_Intensity_Among_Pharmaceutical_Formulations_and_APIs_Peers\" title=\"Competitive Intensity Among Pharmaceutical Formulations and APIs Peers\">Competitive Intensity Among Pharmaceutical Formulations and APIs Peers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Liquidity_Risk_and_FII_Selling_Pressure\" title=\"Liquidity Risk and FII Selling Pressure\">Liquidity Risk and FII Selling Pressure<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#How_to_Invest_in_CORONA_Remedies\" title=\"How to Invest in CORONA Remedies\">How to Invest in CORONA Remedies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#FAQs_on_CORONA_Remedies_Share_Price_Target_2026\" title=\"FAQs on CORONA Remedies Share Price Target 2026\">FAQs on CORONA Remedies Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#What_is_the_CORONA_Remedies_share_price_target_for_2026\" title=\"What is the CORONA Remedies share price target for 2026?\">What is the CORONA Remedies share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#What_was_the_CORONA_Remedies_share_price_target_for_2025\" title=\"What was the CORONA Remedies share price target for 2025?\">What was the CORONA Remedies share price target for 2025?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#Is_CORONA_Remedies_a_good_investment_at_Rs_1833\" title=\"Is CORONA Remedies a good investment at Rs 1,833?\">Is CORONA Remedies a good investment at Rs 1,833?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#What_are_the_key_risks_to_the_CORONA_Remedies_share_price_target_2026\" title=\"What are the key risks to the CORONA Remedies share price target 2026?\">What are the key risks to the CORONA Remedies share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#What_is_the_52_week_high_and_low_of_CORONA_Remedies\" title=\"What is the 52 week high and low of CORONA Remedies?\">What is the 52 week high and low of CORONA Remedies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#What_are_the_main_growth_catalysts_for_CORONA_Remedies_in_2026\" title=\"What are the main growth catalysts for CORONA Remedies in 2026?\">What are the main growth catalysts for CORONA Remedies in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#How_does_CORONA_Remedies_compare_to_its_peers\" title=\"How does CORONA Remedies compare to its peers?\">How does CORONA Remedies compare to its peers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price-target-2026\/#What_is_the_CORONA_Remedies_share_price_target_for_2027\" title=\"What is the CORONA Remedies share price target for 2027?\">What is the CORONA Remedies share price target for 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"CORONA_Remedies_Share_Price_Target_2026_Key_Takeaways\"><\/span><strong>CORONA Remedies Share Price Target 2026: Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>CORONA Remedies share price target 2026:<\/strong> Rs 2,200 (20% upside from CMP Rs 1,833)<\/li>\n<li><strong>Bull case:<\/strong> Rs 2,650 | <strong>Bear case:<\/strong> Rs 1,450<\/li>\n<li><strong>Ticker:<\/strong> CORONA | <strong>Sector:<\/strong> Pharmaceutical Formulations and APIs | <strong>MCap:<\/strong> Rs 1,833 crore<\/li>\n<li><strong>52W range:<\/strong> Rs 1,270 to Rs 3,007 | <strong>PE:<\/strong> 25x<\/li>\n<li><strong>Key catalyst:<\/strong> Q4 FY26 results and FY27 earnings confirmation in 2026<\/li>\n<li><strong>Key risk:<\/strong> FY27 earnings miss or FII outflows from Indian equities<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"CORONA_Remedies_Company_Overview\"><\/span><strong>CORONA Remedies Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>CORONA Remedies (NSE: CORONA) is an Ahmedabad-based pharmaceutical company manufacturing oncology, hormonal, and specialty formulations, along with APIs for regulated export markets, with a growing branded prescription portfolio. At CMP Rs 1,833 against a 52 week range of Rs 1,270 to Rs 3,007, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 1,833 crore with trailing PE of 25x. Compared to peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals, CORONA Remedies is positioned as a potential re-rating candidate toward the Rs 2,200 price objective on FY27 earnings delivery.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>CORONA<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceutical Formulations and APIs<\/td>\n<\/tr>\n<tr>\n<td>CMP (2026)<\/td>\n<td>Rs 1,833<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 3,007<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 1,270<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 1,833 crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing PE<\/td>\n<td>25x<\/td>\n<\/tr>\n<tr>\n<td>12-Month Analyst Target<\/td>\n<td>Rs 2,200<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 2,650<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 1,450<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #E8EAFF; border-radius: 14px; padding: 28px 32px 24px 32px; margin: 24px 0; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,sans-serif; cursor: pointer; max-width: 100%; box-sizing: border-box;\">\n<p style=\"font-size: 20px; font-weight: bold; color: #0a0a23; margin: 0 0 12px 0; line-height: 1.3;\">3 Stocks Building Serious Momentum Right Now<\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">When <strong style=\"color: #0a0a23;\">Univest analysts<\/strong> identify high-conviction opportunities, <em>investors pay attention.<\/em><\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">Our research team has shortlisted the <strong style=\"color: #0a0a23;\">Top Stocks to Buy<\/strong> based on market momentum, sector trends &amp; growth potential for 2026.<\/p>\n<ul style=\"margin: 0 0 16px 20px; padding: 0; color: #3a3a5c; font-size: 15px; line-height: 1.8;\">\n<li>Discover stocks investors are actively accumulating<\/li>\n<li>High-conviction opportunities backed by research<\/li>\n<li>Designed for the next phase of market growth<\/li>\n<\/ul>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 20px 0;\">Unlock the latest <a style=\"color: #3b7fff; font-weight: bold; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">Top Stock Picks<\/a> now on Univest<\/p>\n<p><a style=\"display: inline-block; background: #3B7FFF; color: #fff; font-size: 15px; font-weight: 600; padding: 13px 28px; border-radius: 50px; letter-spacing: 0.2px; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">See the Stocks \u2192<\/a><\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_CORONA_Remedies_Share_Price_Target_Set_at_Rs_2200_for_2026\"><\/span><strong>Why Is the CORONA Remedies Share Price Target Set at Rs 2,200 for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Recovery_and_Revenue_Acceleration\"><\/span><strong>FY27 Earnings Recovery and Revenue Acceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>CORONA Remedies share price target<\/strong> of Rs 2,200 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating. The Rs 2,200 price objective represents the base case with FY27 execution as the key variable.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Structural_Sector_Tailwinds_in_Pharmaceutical_Formulations_and_APIs\"><\/span><strong>Structural Sector Tailwinds in Pharmaceutical Formulations and APIs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Pharmaceutical Formulations and APIs sector is expanding on the back of India&#8217;s domestic demand growth, PLI scheme support, and rising corporate investment. CORONA Remedies&#8217;s position among peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 2,650 bull case to materialise.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\"><\/span><strong>RBI Rate Cut Cycle and Lower Cost of Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve CORONA Remedies&#8217;s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 2,200 analyst consensus.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Union_Budget_2026-27_Capex_Push_and_Policy_Support\"><\/span><strong>Union Budget 2026-27 Capex Push and Policy Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Budget 2026-27&#8217;s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for CORONA Remedies&#8217;s Pharmaceutical Formulations and APIs operations, improving the probability of achieving the Rs 2,200 price objective through FY27 earnings delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FII_Flow_Normalisation_After_the_2026_Tariff_Shock\"><\/span><strong>FII Flow Normalisation After the 2026 Tariff Shock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 25x PE, CORONA Remedies is positioned as a beneficiary of institutional reallocation, providing a tailwind toward the Rs 2,650 bull case over the medium term.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"CORONA_Remedies_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\"><\/span><strong>CORONA Remedies Share Price Targets: Short Term, 12 Month, and Long Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_CORONA_Remedies_Share_Price_Target\"><\/span><strong>Short Term CORONA Remedies Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Near-term support for CORONA Remedies is anchored close to the 52 week low of Rs 1,270. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors can use the 52 week low as an entry reference while awaiting FY27 earnings confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12-Month_CORONA_Remedies_Share_Price_Target_2026\"><\/span><strong>12-Month CORONA Remedies Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month <strong>CORONA Remedies share price target 2026<\/strong> is Rs 2,200, implying approximately 20 percent upside from CMP Rs 1,833. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Track live on NSE ticker CORONA.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Long_Term_CORONA_Remedies_Share_Price_Target_FY27_to_FY28\"><\/span><strong>Long Term CORONA Remedies Share Price Target: FY27 to FY28<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>long term CORONA Remedies share price target<\/strong> for FY27 to FY28 is Rs 2,650 in the bull case, requiring full earnings delivery, re-rating among peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals, and sustained institutional buying over a 2 to 3 year horizon.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_Scenarios_for_CORONA_Remedies_in_2026\"><\/span><strong>Bull Case and Bear Case Scenarios for CORONA Remedies in 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_CORONA_Remedies_Share_Price_Target_Rs_2650\"><\/span><strong>Bull Case CORONA Remedies Share Price Target: Rs 2,650<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bull case CORONA Remedies share price target<\/strong> of Rs 2,650 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations and APIs tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 1,833, this represents approximately 45 percent potential upside.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_CORONA_Remedies_Share_Price_Target_Rs_1450\"><\/span><strong>Bear Case CORONA Remedies Share Price Target: Rs 1,450<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bear case CORONA Remedies share price target<\/strong> of Rs 1,450 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 1,270.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target<\/th>\n<th>Key Conditions<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 2,650<\/td>\n<td>FY27 beat, sector re-rating, FII inflows<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Analyst Target)<\/td>\n<td>Rs 2,200<\/td>\n<td>In-line FY27 delivery, partial FII recovery<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 1,450<\/td>\n<td>FY27 miss, guidance cut, FII outflows persist<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_That_Could_Derail_the_CORONA_Remedies_2026_Price_Objective\"><\/span><strong>Key Risks That Could Derail the CORONA Remedies 2026 Price Objective<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Global_Macro_and_US_Tariff_Headwinds\"><\/span><strong>Global Macro and US Tariff Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the <strong>CORONA Remedies share price target<\/strong> of Rs 2,200, with FII outflows being the direct transmission mechanism to Indian equity valuations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Miss_and_Guidance_Risk\"><\/span><strong>FY27 Earnings Miss and Guidance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>An FY27 earnings miss or downward guidance revision would compress valuation multiples. This is the most direct company-specific risk to the Rs 2,200 analyst price objective. Investors must monitor quarterly results and management commentary closely.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Intensity_Among_Pharmaceutical_Formulations_and_APIs_Peers\"><\/span><strong>Competitive Intensity Among Pharmaceutical Formulations and APIs Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Intensifying competition from peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals could compress CORONA Remedies&#8217;s market share and pricing power. This structural risk must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 2,200 analyst target for 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_Risk_and_FII_Selling_Pressure\"><\/span><strong>Liquidity Risk and FII Selling Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_CORONA_Remedies\"><\/span><strong>How to Invest in CORONA Remedies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data<\/strong><\/a><\/p>\n<p>Before considering any investment based on the <strong>CORONA Remedies share price target<\/strong> of Rs 2,200, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Formulations and APIs sector demand.<\/p>\n<p>Open a Demat account with a SEBI registered stockbroker to trade CORONA Remedies (NSE: CORONA) with regulatory protection. Study the competitive landscape among peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals before executing any position.<\/p>\n<p>Plan your entry using the 52 week low of Rs 1,270 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 2,200 price objective. Always set a stop loss below the 52 week low.<\/p>\n<p>Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.<\/p>\n<p><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track CORONA Remedies&#8217;s live share price and receive daily stock recommendations.<\/em><\/p>\n<div style=\"background: #C0392B; padding: 20px 24px; border-radius: 4px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 15px; font-weight: bold; margin: 0; line-height: 1.7;\"><strong>Disclaimer Note:<\/strong> The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_CORONA_Remedies_Share_Price_Target_2026\"><\/span><strong>FAQs on CORONA Remedies Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_CORONA_Remedies_share_price_target_for_2026\"><\/span><strong>What is the CORONA Remedies share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The CORONA Remedies share price target 2026 is Rs 2,200, implying approximately 20 percent upside from CMP Rs 1,833. Bull case is Rs 2,650, bear case is Rs 1,450.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_CORONA_Remedies_share_price_target_for_2025\"><\/span><strong>What was the CORONA Remedies share price target for 2025?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 2025 price objective for CORONA Remedies was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 2,200, reflecting FY27 growth potential from CMP Rs 1,833.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_CORONA_Remedies_a_good_investment_at_Rs_1833\"><\/span><strong>Is CORONA Remedies a good investment at Rs 1,833?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> At Rs 1,833, CORONA Remedies offers potential upside toward Rs 2,200 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance and portfolio goals. Consult a SEBI registered financial advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_CORONA_Remedies_share_price_target_2026\"><\/span><strong>What are the key risks to the CORONA Remedies share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks to the CORONA Remedies share price target of Rs 2,200 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations and APIs. Monitoring quarterly results is essential.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_of_CORONA_Remedies\"><\/span><strong>What is the 52 week high and low of CORONA Remedies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 52 week high of CORONA Remedies is Rs 3,007 and the 52 week low is Rs 1,270. At CMP Rs 1,833, the stock is below its 52 week high and offers potential upside toward the Rs 2,200 price objective.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_growth_catalysts_for_CORONA_Remedies_in_2026\"><\/span><strong>What are the main growth catalysts for CORONA Remedies in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations and APIs sector tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_CORONA_Remedies_compare_to_its_peers\"><\/span><strong>How does CORONA Remedies compare to its peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> CORONA Remedies operates in Pharmaceutical Formulations and APIs alongside peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals. At CMP Rs 1,833 with MCap Rs 1,833 crore, it is a potential re-rating candidate toward the CORONA Remedies share price target of Rs 2,200 on FY27 delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_CORONA_Remedies_share_price_target_for_2027\"><\/span><strong>What is the CORONA Remedies share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The long-term CORONA Remedies share price target for FY27 to FY28 is Rs 2,650 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the CORONA Remedies share price target for 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The CORONA Remedies share price target 2026 is Rs 2,200, implying approximately 20 percent upside from CMP Rs 1,833. Bull case is Rs 2,650, bear case is Rs 1,450.\"}},{\"@type\":\"Question\",\"name\":\"What was the CORONA Remedies share price target for 2025?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The 2025 price objective for CORONA Remedies was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 2,200, reflecting FY27 growth potential from CMP Rs 1,833.\"}},{\"@type\":\"Question\",\"name\":\"Is CORONA Remedies a good investment at Rs 1,833?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"At Rs 1,833, CORONA Remedies offers potential upside toward Rs 2,200 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance and portfolio goals. Consult a SEBI registered financial advisor before investing.\"}},{\"@type\":\"Question\",\"name\":\"What are the key risks to the CORONA Remedies share price target 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key risks to the CORONA Remedies share price target of Rs 2,200 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations and APIs. Monitoring quarterly results is essential.\"}},{\"@type\":\"Question\",\"name\":\"What is the 52 week high and low of CORONA Remedies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The 52 week high of CORONA Remedies is Rs 3,007 and the 52 week low is Rs 1,270. At CMP Rs 1,833, the stock is below its 52 week high and offers potential upside toward the Rs 2,200 price objective.\"}},{\"@type\":\"Question\",\"name\":\"What are the main growth catalysts for CORONA Remedies in 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations and APIs sector tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.\"}},{\"@type\":\"Question\",\"name\":\"How does CORONA Remedies compare to its peers?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"CORONA Remedies operates in Pharmaceutical Formulations and APIs alongside peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals. At CMP Rs 1,833 with MCap Rs 1,833 crore, it is a potential re-rating candidate toward the CORONA Remedies share price target of Rs 2,200 on FY27 delivery.\"}},{\"@type\":\"Question\",\"name\":\"What is the CORONA Remedies share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The long-term CORONA Remedies share price target for FY27 to FY28 is Rs 2,650 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The CORONA Remedies share price target 2026 is Rs 2,200, ~20% upside from CMP Rs 1,833. Bull Rs 2,650, bear Rs 1,450. 2026.<\/p>\n","protected":false},"author":35,"featured_media":124008,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-123811","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1781855284:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_focus_keyword":["CORONA Remedies Share Price Target 2026"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["CORONA Remedies Share Price Target 2026: Rs 2,200 Analyst Forecast"],"rank_math_description":["The CORONA Remedies share price target 2026 is Rs 2,200, ~20% upside from CMP Rs 1,833. Bull Rs 2,650, bear Rs 1,450. 2026."],"_thumbnail_id":["124008"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["19439"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/CORONA-Remedies-Share-Price-Target-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/123811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=123811"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/123811\/revisions"}],"predecessor-version":[{"id":124010,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/123811\/revisions\/124010"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/124008"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=123811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=123811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=123811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}